

THIS CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION

If you are in any doubt as to any aspect of this circular or as to the action to be taken, you should consult your licensed securities dealer, bank manager, solicitor, professional accountant or other professional adviser.

If you have sold or transferred all your shares in Meilleure Health International Industry Group Limited, you should at once hand this circular and the accompanying form of proxy to the purchaser or the transferee or to the bank, licensed securities dealer or other agent through whom the sale or transfer was effected for transmission to the purchaser or the transferee.

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this circular, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this circular.



美瑞健康国际产业集团
Meilleure Health International Industry Group

MEILLEURE HEALTH INTERNATIONAL INDUSTRY GROUP LIMITED

美瑞健康國際產業集團有限公司

(Incorporated in Bermuda with limited liability)

(Stock Code: 2327)

**GENERAL MANDATES TO REPURCHASE SHARES
AND TO ISSUE NEW SHARES;
RE-ELECTION OF DIRECTORS;
PROPOSED PAYMENT OF FINAL DIVIDEND;
CLOSURE OF REGISTER OF MEMBERS;
AND
NOTICE OF ANNUAL GENERAL MEETING**

A notice convening the AGM to be held at Units 5906–5912, 59/F, The Center, 99 Queen's Road Central, Central, Hong Kong on Thursday, 27 June 2024 at 11:00 a.m. is set out on pages 14 to 18 of this circular. A form of proxy for use by the Shareholders at the AGM is enclosed. Whether or not you intend to attend and vote at the AGM in person, please complete the form of proxy in accordance with the instructions set out therein and return it to the Company's Hong Kong branch share registrar, Tricor Standard Limited at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong as soon as possible but in any event not later than 48 hours before the time appointed for holding the AGM or any adjourned meeting (as the case may be). Completion and return of the form of proxy will not preclude you from attending and voting in person at the AGM or any adjourned meeting (as the case may be) should you so wish.

29 April 2024

CONTENTS

	<i>Page</i>
Definitions	1
Letter from the Board	
Introduction	3
Repurchase Mandate	4
General Mandate	4
Re-election of Directors	5
Proposed payment of Final Dividend	5
Annual General Meeting	5
Voting at the Annual General Meeting	5
Closure of Register of Members	6
Recommendation	6
Appendix I — Explanatory Statement of the Repurchase Mandate	7
Appendix II — Details of the Re-elected Directors	10
Notice of Annual General Meeting	14

DEFINITIONS

In this circular, the following expressions shall have the following meanings unless the context indicates otherwise:

“AGM”	the annual general meeting of the Company to be held at Units 5906–5912, 59/F, The Center, 99 Queen’s Road Central, Central, Hong Kong on Thursday, 27 June 2024 at 11:00 a.m. for the purposes of considering the businesses set out in the AGM Notice and, if thought fit, passing the resolutions set out therein, or any adjourned meeting (as the case may be)
“AGM Notice”	the notice for convening the AGM as set out on pages 14 to 18 in this circular
“Board”	the board of Directors
“Bye-laws”	the bye-laws of the Company
“Company”	Meilleure Health International Industry Group Limited, an exempted company incorporated in Bermuda with limited liability and the Shares of which are listed on the main board of the Stock Exchange
“Director(s)”	the director(s) of the Company
“Final Dividend”	the proposed final dividend of HK0.4 cents per Share for the year ended 31 December 2023 to the Shareholders whose names appear on the Record Date
“General Mandate”	the general mandate to allot, issue and deal with new Shares not exceeding 20% of the total number of Shares in issue as at the date of passing of the ordinary resolution in relation thereof
“Group”	the Company and its subsidiaries
“HK\$”	Hong Kong dollar, the lawful currency of Hong Kong
“Hong Kong”	the Hong Kong Special Administrative Region of the PRC
“Latest Practicable Date”	19 April 2024, being the latest practicable date prior to the printing of this circular for ascertaining certain information contained herein
“Listing Rules”	The Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited as amended, supplemented or otherwise modified from time to time

DEFINITIONS

“PRC”	the People’s Republic of China, and for the purpose of this circular, excludes Hong Kong, the Macau Special Administrative Region and Taiwan region
“Record Date”	Tuesday, 6 August 2024, being the record date for determining entitlements of the Shareholders to the Final Dividend
“Register of Members”	the principal or branch register of members of the Company maintained in Bermuda or Hong Kong, respectively
“Repurchase Mandate”	the authority to repurchase fully paid up Shares of up to 10% of the total number of Shares in issue as at the date of passing of the ordinary resolution in relation thereof
“SFC”	the Securities and Futures Commission in Hong Kong
“SFO”	the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) as amended, supplemented or otherwise modified from time to time
“Share(s)”	the ordinary share(s) of HK\$0.01 each in the share capital of the Company
“Shareholder(s)”	the holder(s) of the Share(s)
“Stock Exchange”	The Stock Exchange of Hong Kong Limited
“Takeovers Code”	The Codes on Takeovers and Mergers as amended, supplemented or otherwise modified from time to time
“%”	per cent

LETTER FROM THE BOARD



美瑞健康国际产业集团
Meilleure Health International Industry Group

MEILLEURE HEALTH INTERNATIONAL INDUSTRY GROUP LIMITED

美瑞健康國際產業集團有限公司

(Incorporated in Bermuda with limited liability)

(Stock Code: 2327)

Executive Directors:

Mr. Zhou Xuzhou (*Co-Chairman*)

Dr. Zeng Wentao (*Co-Chairman*)

Ms. Zhou Wen Chuan

(Vice Chairman and Chief Executive Officer)

Registered office:

Clarendon House

2 Church Street

Hamilton HM 11

Bermuda

Non-Executive Director:

Dr. Mao Zhenhua

*Head office and principal place of
business in Hong Kong:*

Unit 2906

Tower 1, Lippo Centre

89 Queensway

Admiralty

Hong Kong

Independent Non-Executive Directors:

Professor Chau Chi Wai, Wilton

Dr. Yang Yu (resigned on 10 April 2024)

Mr. Chen Shi (appointed on 10 April 2024)

Mr. Wu Peng

29 April 2024

To the Shareholders

Dear Sir/Madam,

**GENERAL MANDATES TO REPURCHASE SHARES
AND TO ISSUE NEW SHARES;
RE-ELECTION OF DIRECTORS;
PROPOSED PAYMENT OF FINAL DIVIDEND;
CLOSURE OF REGISTER OF MEMBERS;
AND
NOTICE OF ANNUAL GENERAL MEETING**

INTRODUCTION

The purpose of this circular is to provide you with information relating to the resolutions to be proposed at the AGM regarding (i) the granting of the Repurchase Mandate to the Directors; (ii) the granting of the General Mandate to the Directors; (iii) the re-election of Directors; and (iv) the proposed payment of the Final Dividend.

LETTER FROM THE BOARD

REPURCHASE MANDATE

At the AGM, an ordinary resolution will be proposed to grant the Repurchase Mandate to the Directors. The authority to be given under the Repurchase Mandate is restricted to the repurchase of Shares on the Stock Exchange in accordance with the Listing Rules.

In accordance with the Listing Rules, an explanatory statement of the Repurchase Mandate is set out in Appendix I of this circular in order to provide you with requisite information reasonably necessary to enable you to make an informed decision on whether to vote for or against the ordinary resolution to be proposed at the AGM for granting the Repurchase Mandate to the Directors.

The full text of the resolution in respect of the Repurchase Mandate is set out in resolution no. 5 in the AGM Notice. As at the Latest Practicable Date, there were 4,093,756,636 Shares in issue and assuming that no new shares are allotted or issued prior to the AGM, the total number of Shares that may be repurchased under the Repurchase Mandate will be 409,375,663 Shares, calculated based on 10% of the total number of shares of the Company in issue as at the date of passing of the ordinary resolution in relation thereto.

GENERAL MANDATE

At the AGM, an ordinary resolution will also be proposed to grant the General Mandate to the Directors. The general mandate granted to the Directors at the last annual general meeting of the Company held on 27 June 2023 will lapse at the conclusion of the AGM. The General Mandate will give the Directors the flexibility and discretion to issue new Shares. In addition, an ordinary resolution will be proposed to extend the General Mandate by adding to it the number of such Shares repurchased under the Repurchase Mandate.

The full texts of the resolutions in respect of the General Mandate and the extension of the General Mandate are set out in resolutions nos. 6 and 7 in the AGM Notice, respectively.

As at the Latest Practicable Date, there were 4,093,756,636 Shares in issue and assuming that no new shares are allotted or issued prior to the AGM, the total number of Shares that may be issued under the General Mandate will be 818,751,327 Shares, calculated based on 20% of the total number of shares of the Company in issue as at the date of passing of the ordinary resolution in relation thereto.

LETTER FROM THE BOARD

RE-ELECTION OF DIRECTORS

Reference is made to the Company's announcement (the “**Announcement**”) dated 10 April 2024 in relation to, among others, changes in the directorships of the Company. As disclosed in the Announcement, the following changes in the directorships of the Company took place and became effective from 10 April 2024:

- (1) Dr. Yang Yu (楊毓) resigned as an independent non-executive Director of the Company owing to his other personal commitments that require his more dedication; and
- (2) Mr. Chen Shi (陳實) was appointed as an independent non-executive Director of the Company.

Pursuant to the Bye-laws, Dr. Zeng Wentao, Mr. Chen Shi and Mr. Wu Peng will retire and, being eligible, will offer themselves for re-election at the AGM. Information on the retiring Directors is set out in Appendix II to this circular.

PROPOSED PAYMENT OF FINAL DIVIDEND

Subject to the approval of Shareholders at the AGM, the Board proposed to pay a final dividend of HK0.4 cents per Share for the year ended 31 December 2023 to the Shareholders whose names appear on the Register of Members as at the close of business on Tuesday, 6 August 2024. The final dividends are expected to be paid in Hong Kong dollars on or before Tuesday, 20 August 2024.

In order to determine the entitlement of the shareholders to receive the proposed final dividend, if approved, the register of members of the Company will be closed from Monday, 5 August 2024 to Tuesday, 6 August 2024, no transfer of the Shares will be registered on that day.

ANNUAL GENERAL MEETING

A notice convening the AGM is set out on pages 14 to 18 of this circular and a form of proxy for use by Shareholders at the AGM is enclosed with this circular. Whether or not you intend to attend and vote at the AGM in person, you are requested to complete the form of proxy in accordance with the instructions set out therein and return it to the Company's branch share registrar in Hong Kong, Tricor Standard Limited at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong as soon as possible but in any event, not less than 48 hours before the time appointed for holding the AGM or any adjourned meeting (as the case may be). Completion and return of the form of proxy will not preclude you from attending and voting in person at the AGM or any adjourned meeting (as the case may be) should you so wish.

VOTING AT THE ANNUAL GENERAL MEETING

Pursuant to the Rule 13.39 of the Listing Rules, all votes of Shareholders at a general meeting must be taken by poll. The chairman of the meeting will therefore demand a poll for every resolution put to the vote at the AGM pursuant to bye-law 66 of the Bye-laws.

LETTER FROM THE BOARD

CLOSURE OF REGISTER OF MEMBERS

The Register of Members for the AGM will be closed from Thursday, 20 June 2024 to Thursday, 27 June 2024, both days inclusive, during which period no transfer of shares will be registered. In order to qualify for attendance at the AGM to be held on Thursday, 27 June 2024, all transfers accompanied by the relevant share certificates must be lodged with the Company's branch share registrar and transfer office in Hong Kong, Tricor Standard Limited, 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong, for registration not later than 4:30 p.m. on Wednesday, 19 June 2024.

RECOMMENDATION

The Directors are of the opinion that the resolutions to be proposed at the AGM as referred in this circular are in the interests of the Company and the Shareholders and recommend the Shareholders to vote in favour of the resolutions to be proposed at the AGM.

Yours faithfully,

For and on behalf of

Meilleure Health International Industry Group Limited

Zhou Wen Chuan

Executive Director and Chief Executive Officer

APPENDIX I EXPLANATORY STATEMENT OF THE REPURCHASE MANDATE

This Appendix serves as an explanatory statement required by Rule 10.06(1)(b) of the Listing Rules to provide you with all the information reasonably necessary to enable you to make an informed decision on whether to vote for or against the ordinary resolution to be proposed at the AGM for granting the Repurchase Mandate to the Directors.

SHAREHOLDERS' APPROVAL

All proposed repurchases of Shares on the Stock Exchange by a company with its primary listing on the Stock Exchange must be approved in advance by an ordinary resolution, either by way of a general mandate or by specific approval.

REASONS FOR SHARE REPURCHASE

The Directors believe that it is in the interests of the Company and Shareholders for the Directors to continue to have general authority from the Shareholders to enable the Company to repurchase Shares on the Stock Exchange. Such repurchases may, depending on market conditions and funding arrangements at the time, lead to an enhancement of the net asset value per Share and/or earnings per Share. Shareholders are assured that such repurchases of Shares will only be made when the Directors believe that they are appropriate and will benefit the Company and Shareholders as a whole.

SHARE CAPITAL

As at the Latest Practicable Date, the Company had 4,093,756,636 Shares in issue.

Subject to the passing of the proposed ordinary resolution approving to grant the Repurchase Mandate to the Directors and on the assumptions that no new Shares are allotted or issued, and no existing Shares are repurchased by the Company prior to the AGM, the exercise of the Repurchase Mandate in full would enable the Company to repurchase a maximum of 409,375,663 Shares, representing 10% of the Shares in issue as at the Latest Practicable Date.

FUNDING OF SHARE REPURCHASE

Any repurchases must be funded out of funds legally available for such purpose in accordance with the Company's memorandum of association and Bye-laws and the laws of Bermuda. Bermuda laws provide that the amount of capital repaid related to a share repurchase may only be paid out of either the capital paid up on the relevant shares, or the funds that would otherwise be available for distribution or dividend or the proceeds of a fresh issue of shares made for the purpose.

The exercise of the Repurchase Mandate in full might have a material adverse impact on the working capital and/or gearing level of the Company as compared with the position disclosed in the Company's annual report for the year ended 31 December 2023. However, the Directors do not intend to exercise the Repurchase Mandate to such extent as would, in the circumstances, have a material adverse impact on the working capital and/or gearing level of the Company unless the Directors consider that such purchases are in the interests of the Company.

DISCLOSURE OF INTERESTS

None of the Directors or, to the best of their knowledge having made all reasonable enquiries, any of their respective close associates (as defined in the Listing Rules) has any present intention, in the event that the Repurchase Mandate is approved by Shareholders, to sell any Share to the Company.

No core connected person (as defined in the Listing Rules) has notified the Company that he/she has a present intention to sell any Share to the Company or has undertaken not to sell any of the Shares held by him/her to the Company, in the event that the Repurchase Mandate is approved by Shareholders.

UNDERTAKING OF THE DIRECTORS

The Directors have undertaken to the Stock Exchange that they will exercise the Repurchase Mandate in accordance with the Listing Rules, the regulations set out in the Company's memorandum of association and Bye-laws and the applicable laws of Bermuda.

EFFECT OF THE TAKEOVERS CODE AND MINIMUM PUBLIC SHAREHOLDING

If on the exercise of the power to repurchase shares pursuant to the Repurchase Mandate, a Shareholder's proportionate interest in the voting rights of the Company increases, such increase will be treated as an acquisition of voting rights for the purpose of Rule 32 of the Takeovers Code. As a result, a Shareholder or a group of Shareholders acting in concert could obtain or consolidate control of the Company and become obliged to make a mandatory offer in accordance with Rules 26 and 32 of the Takeovers Code.

As at the Latest Practicable Date, Mr. Zhou Xuzhou (the "**Controlling Shareholder**") was interested in, beneficially and through controlled corporation, an aggregate of 2,303,896,761 Shares, representing approximately 56.28% of the issued share capital of the Company. If the Directors were to exercise the Repurchase Mandate in full, such Shares would represent approximately 62.53% of the then issued share capital of the Company. The Directors are not aware of any consequences which would arise under the Takeovers Code as a result of any repurchase of Shares pursuant to the Repurchase Mandate.

Pursuant to Rule 8.08 of the Listing Rules, the Company should maintain at least 25% of the issued share capital of the Company be held by the public. Based on the current shareholding of the Controlling Shareholder, if the Directors were to exercise the Repurchase Mandate in full, it would not result in the amount of Shares held by the public being reduced to less than 25%.

SHARE REPURCHASES BY THE COMPANY

The Company did not repurchase any of its Shares (whether on the Stock Exchange or otherwise) in the six months preceding the Latest Practicable Date.

APPENDIX I EXPLANATORY STATEMENT OF THE REPURCHASE MANDATE

SHARE PRICES

The highest and lowest prices at which the Shares had been traded on the Stock Exchange during each of the previous twelve months preceding the Latest Practicable Date were as follows:

	Price per Share	
	Highest <i>HK\$</i>	Lowest <i>HK\$</i>
2023		
April	0.295	0.270
May	0.280	0.245
June	0.290	0.265
July	0.295	0.255
August	0.290	0.250
September	0.275	0.255
October	0.280	0.246
November	0.255	0.238
December	0.246	0.233
2024		
January	0.239	0.199
February	0.210	0.146
March	0.155	0.115
April (Up to the Latest Practicable Date)	0.149	0.117

Set out below are the details of the Directors who retire and, being eligible, will offer themselves for re-election at the AGM pursuant to the Bye-laws:

Dr. Zeng Wentao (“**Dr. Zeng**”), aged 60, was appointed as an independent non-executive Director of the Company on 18 October 2017, and was re-designated as an executive Director of the Company on 27 May 2019 and was appointed as a co-chairman of the Company on 20 June 2019. He is a member of the remuneration committee of the Company and the strategic committee of the Company.

Dr. Zeng graduated from Wuhan University with a doctoral degree in Economics. Dr. Zeng founded Hainan Sanyou Real Estate Company Limited (海南三友房地產有限公司) in Hainan in 1990 and acted as its general manager. In 1995, he founded Wuhan Yin Hai Property Company Limited (武漢銀海置業有限公司), which was principally engaged in real estate development and technology investment, and acted as its chief executive officer. He has been the chief executive officer of Zhongjia Capital (Wuhan) Investment Management Company Limited (中珈資本(武漢)投資管理有限公司) since March 2017. He is a part-time professor of Zhongnan University of Economics and Law, a member of Zhongnan University of Economics and Law Educational Development Fund and a standing council member of Dong Fureng Foundation (董輔弼基金會). He was the vice-chairman of the 12th and 13th Federation of Industry and Commerce of Wuhan City (武漢市工商聯) and a member of the 11th and 12th People’s Consultative Conference of Wuhan City. Dr. Zeng has been a Counselor of the Healthcare Industry Union of Wuhan University Alumni Entrepreneur Association (武漢大學校友企業家聯誼會健康產業聯盟), an organisation dedicated to the promotion of co-operations in the healthcare industry among entrepreneurs who are alumni of Wuhan University, since July 2017. By taking this position, Dr. Zeng has gained an understanding of the healthcare business and has built good relationships with certain entrepreneurs and market players in the healthcare industry. In 2018, Dr. Zeng was appointed as a researcher in health economics of Dong Fureng Economic & Social Development School of Wuhan University, which demonstrated the recognition of Dr. Zeng’s knowledge in health economics by the said organisation and has enabled Dr. Zeng to use his managerial experience to contribute to the research work in the health economics area.

Dr. Zeng Wentao has no relationship with any directors, senior management or substantial or controlling shareholders of the Company, and he is not a director of any other members of the Group. Save as disclosed above, Dr. Zeng Wentao has not held directorship in any listed company in the last three years.

Dr. Zeng Wentao has entered into a service contract with the Company for a term of three years commencing on 27 May 2022 and ending on 26 May 2025. He is entitled to an annual remuneration of HK\$300,000 as determined by the Board, subject to annual review with reference to his duties and responsibilities as well as the prevailing market conditions.

As at the Latest Practicable Date, Dr. Zeng Wentao had interest in 77,500,500 Shares, representing 1.89% in the total issued Shares within the meaning of Part XV of the SFO (including his interest in 75,000,000 Shares beneficially owned by him, representing 1.83% in the total issued Shares, as well as his interest in 2,500,500 Shares that fall to be issued upon full exercise of the share options granted to him, representing 0.06% in the total issued Shares).

Mr. Chen Shi (“**Mr. Chen**”), aged 62, was appointed as an independent non-executive Director on 10 April 2024. He is the chairman of the remuneration committee of the Company and a member of the audit committee of the Company.

Mr. Chen obtained a bachelor’s degree and a master’s degree in economics from Wuhan University in August 1982 and July 1985, respectively. He later obtained a doctorate in economics from the Graduate School of Chinese Academy of Social Sciences in July 1989. Mr. Chen has over 30 years of working experience. Mr. Chen served as deputy head and then the head of the Policy Division of Social and Economic Development Research Center of the People’s Government of Hainan Province from July 1989 to November 1994. He served as a deputy general manager of Yat Chau Holdings Limited from December 1994 to February 1998. He then served as a deputy general manager of Cityford Dyeing & Printing Industrial Limited from March 1998 to December 2001. From January 2002 to February 2013, Mr. Chen served as the president of Caricom Limited. He was previously a director of Partners Financial Holdings Limited from November 2012 to July 2013 and a non-executive director of LDK Solar Co., Ltd. (a company listed on the New York Stock Exchange Inc.) from March 2014 to May 2016. He has been a director of Mountain China Resorts (Holdings) Limited (a former company listed on the TSX Venture Exchange in Canada and delisted on 19 January 2023) since February 2012 and an executive director and chief executive office of Good Resources Holdings Limited (a former company listed on the Main Board of the Stock Exchange, stock code: 109 and delisted on 4 May 2022) since July 2019. Mr. Chen was first appointed as a non-executive director of Shunfeng International Clean Energy Limited (stock code: 1165), a company listed on the Stock Exchange, from March 2013 to September 2013 and has later been appointed as an executive director since 1 August 2017.

Mr. Chen Shi has no relationship with any Directors, senior management, substantial or controlling shareholders of the Company, and he is not a director of any other members of the Group. Save as disclosed above and as far as Mr. Chen Shi is aware, Mr. Chen Shi did not hold directorships of other public companies, the securities of which are listed on any securities market in Hong Kong or overseas in the last three years.

Mr. Chen Shi has entered into a letter of appointment with the Company for a term of one year commencing on 10 April 2024 and ending on 9 April 2025. Mr. Chen Shi is entitled to an annual remuneration of HK\$120,000 as determined with reference to Mr. Chen Shi’s experience, duties and responsibilities with the Group, as well as the Group’s performance and the prevailing market, and is subject to the annual review by the remuneration committee of the Board and the Board.

As at the Latest Practicable Date, Mr. Chen Shi did not have, directly or indirectly, and was not deemed to have any interests in any shares, underlying shares or debentures (as defined under Part XV of the SFO) of the Company which are required to be disclosed pursuant to Part XV of the SFO.

Mr. Wu Peng (“**Mr. Wu**”), aged 42, was appointed as an independent non-executive Director on 27 May 2019. He is a member of the nomination committee of the Company.

Mr. Wu graduated from Tsinghua University with a bachelor’s degree in information systems in July 2004 and a doctoral degree (with supply chain management as a key research area) in January 2010. From September 2005 to January 2010, Mr. Wu worked as a research assistant in the Humanities Key Research Base of the Ministry of Education (教育部人文社科重點研究基地) of the PRC and the Research Centre for Contemporary Management Tsinghua University (清華大學現代管理研究中心), where he participated in the study of pharmaceutical products supply chain management strategies. In this position, Mr. Wu conducted investigations and research on the production and operation processes of a number of large-sized pharmaceutical companies in the PRC and gained a good understanding of their supply chain management. From March 2010 to November 2012, Mr. Wu was a lecturer at the school of Business Administration of South China University of Technology and was mainly involved in teaching and researching green supply chain management. During this period, from November 2010 to April 2012, Mr. Wu was also a postdoctoral researcher at The Martin Centre for Architectural and Urban Studies of the University of Cambridge, where he was engaged in low-carbon supply chain and low-carbon urban planning and design research work. Since December 2012, Mr. Wu has been teaching green supply chain management and engaging in the research work in this area in the Business School of Sichuan University, first as an associate professor from December 2012 to September 2017 and subsequently as a professor since September 2017. During a five-year period from 2012 to 2017, Mr. Wu was involved in an industrial chain optimisation consulting project, through which he further gained experience in the supply chain management research area. Mr. Wu has been a Counselor of the Society of Management Science and Engineering of China (中國管理科學與工程學會理事) since October 2018.

Mr. Wu has no relationship with any Director, senior management, substantial or controlling shareholder of the Company, and he is not a director of any other members of the Group.

Mr. Wu has served as an independent director of LightInTheBox Holding Co., Ltd., an online retail company whose shares are listed on the New York Stock Exchange, since January 2019. Save as disclosed above, Mr. Wu did not hold any directorships of any other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years.

Mr. Wu has entered into a letter of appointment with the Company for a term of three years commencing on 20 June 2022 and ending on 19 June 2025. Mr. Wu is entitled to an annual remuneration of HK\$120,000 as determined by the Board, subject to annual review with reference to his duties and responsibilities as well as the prevailing market conditions.

As at the Latest Practicable Date, Mr. Wu did not have, directly or indirectly, and was not deemed to have any interests in any shares, underlying shares or debentures (as defined under Part XV of the SFO) of the Company which are required to be disclosed pursuant to Part XV of the SFO.

There is nothing which needs to be disclosed pursuant to Rule 13.51(2) of the Listing Rules nor is there anything which needs to be brought to the attention of the Shareholders in connection with the above retiring Directors.

** For identification purposes only*

NOTICE OF ANNUAL GENERAL MEETING



美瑞健康国际产业集团
Meilleure Health International Industry Group

MEILLEURE HEALTH INTERNATIONAL INDUSTRY GROUP LIMITED

美瑞健康國際產業集團有限公司

(Incorporated in Bermuda with limited liability)

(Stock Code: 2327)

NOTICE IS HEREBY GIVEN that the annual general meeting of Meilleure Health International Industry Group Limited (the “**Company**”) will be held at Units 5906–5912, 59/F, The Center, 99 Queen’s Road Central, Central, Hong Kong on 27 June 2024 at 11:00 a.m. (the “**AGM**”) for the following purposes:

AS ORDINARY BUSINESS

1. To receive and consider the audited financial statements and the reports of the directors and auditors of the Company and its subsidiaries for the year ended 31 December 2023.
2. To declare and approve a final dividend of HK0.4 cents per Share in respect of the year ended 31 December 2023.
3. To re-elect retiring directors of the Company and to authorise the board of directors of the Company to fix their remuneration.
4. To re-appoint ZHONGHUI ANDA CPA Limited as the auditor of the Company and to authorise the board of directors of the Company to fix their remuneration.

NOTICE OF ANNUAL GENERAL MEETING

AS SPECIAL BUSINESS

To consider and, if thought fit, to pass with or without amendments, each of the following resolutions as ordinary resolutions of the Company:

ORDINARY RESOLUTIONS

5. “**THAT:**

- (a) subject to paragraph (b) of this resolution, the exercise by the Directors of the Company during the Relevant Period (as defined in paragraph (c) of this resolution) of all the powers of the Company to repurchase shares of HK\$0.01 each in the capital of the Company on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) or on any other stock exchange on which the securities of the Company may be listed and recognized by the Securities and Futures Commission of Hong Kong and the Stock Exchange for this purpose, subject to and in accordance with all applicable laws and the requirement of the Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited or of any other stock exchange as amended from time to time, be and is hereby generally and unconditionally approved;
- (b) the aggregate number of shares of the Company (the “**Shares**”) to be repurchased during the Relevant Period pursuant to the approval in paragraph (a) of this resolution shall not exceed 10% of the total number of shares of the Company in issue on the date of passing of this resolution; and
- (c) for the purposes of this resolution, “**Relevant Period**” means the period from the passing of this resolution until whichever is the earliest of:
 - (i) the conclusion of the next annual general meeting of the Company;
 - (ii) the expiration of the period within which the next annual general meeting of the Company is required by the bye-laws of the Company or any applicable law to be held; or
 - (iii) the revocation or variation of the authority given under this resolution by ordinary resolution of the shareholders of the Company in general meeting.”

NOTICE OF ANNUAL GENERAL MEETING

6. “**THAT:**

- (a) subject to paragraphs (b) and (c) of this resolution, the granting of an unconditional general mandate to the directors of the Company during the Relevant Period (as defined in paragraph (d) of this resolution) to allot, issue and deal with additional shares in the capital of the Company and to make or grant offers, agreements, options (including warrants, bonds, debentures, notes and other securities which carry rights to subscribe for or are convertible into shares of the Company) which might require the exercise of such power be and is hereby generally and unconditionally approved;
- (b) the unconditional general mandate under paragraph (a) of this resolution shall not extend the Relevant Period save the directors of the Company may during the Relevant Period make or grant offers, agreements and options (including warrants, bonds, debentures, notes and other securities which carry rights to subscribe for or are convertible into shares of the Company) during the Relevant Period which would or might require the exercise of such power after the end of the Relevant Period;
- (c) the aggregate number of Shares allotted or agreed conditionally or unconditionally to be allotted by the directors of the Company pursuant to the general mandate in paragraph (a) of this resolution, otherwise than pursuant to (i) a Rights Issue (as defined in paragraph (d) of this resolution) or (ii) any scrip dividend or similar arrangement providing for the allotment of shares in lieu of the whole or part of a dividend on shares of the Company in accordance with the bye-laws of the Company or (iii) any share option scheme of the Company or (iv) the exercise of any rights of subscription or conversion under any existing warrants, bonds, debentures, notes and other securities issued by the Company which carry rights to subscribe for or are convertible into shares of the Company, shall not exceed 20% of the total number of shares of the Company in issue on the date of passing of this resolution; and
- (d) for the purposes of this resolution, “**Relevant Period**” means the period from the passing of this resolution until whichever is the earliest of:
 - (i) the conclusion of the next annual general meeting of the Company;
 - (ii) the expiration of the period within which the next annual general meeting of the Company is required by the bye-laws of the Company or any applicable law to be held; or
 - (iii) the revocation or variation of the authority given under this resolution by ordinary resolution of the shareholders of the Company in general meeting; and

NOTICE OF ANNUAL GENERAL MEETING

“**Rights Issue**” means an offer of shares in the Company, open for a period fixed by the directors to the holders of shares, whose names appear on the register of members of the Company on a fixed record date in proportion to their then holdings of such shares as at that date (subject to such exclusions or other arrangements as the directors may deem necessary or expedient in relation to fractional entitlements or having regard to any restrictions or obligations under the laws of, or the requirements of any recognised regulatory body or any stock exchange in, any territory applicable to the Company).”

7. “**THAT** conditional upon the passing of resolutions nos. 5 and 6 as set out in the notice convening the meeting of which this resolution forms part, the general mandate referred to in resolution no. 6 as set out in the notice convening the meeting of which this resolution forms part be and is hereby extended by the addition to the aggregate number of Shares which may be allotted and issued or agreed conditionally or unconditionally to be allotted and issued by the directors of the Company pursuant to such general mandate of an amount representing the aggregate number of Shares repurchased by the Company since the granting of the said general mandate pursuant to the exercise by the directors of the Company of the powers of the Company to purchase such shares provided that such amount shall not exceed 10% of the total number of shares of the Company in issue on the date of passing of this resolution.”

By Order of the Board
Meilleure Health International Industry Group Limited
Zhou Wen Chuan
Executive Director and Chief Executive Officer

Hong Kong, 29 April 2024

NOTICE OF ANNUAL GENERAL MEETING

Notes:

1. A member entitled to attend and vote at the meeting is entitled to appoint another person as his proxy to attend and vote on his behalf. A member who is the holder of two or more shares may appoint more than one proxy to attend on the same occasion. A proxy need not be a member of the Company. If more than one proxy is appointed, the appointment shall specify the number and class of shares in respect of which each such proxy is so appointed.
2. To be valid, the instrument appointing a proxy and the power of attorney or other authority, if any, under which it is signed, or a notarially certified copy of such power or authority, must be deposited at the Company's branch share registrars in Hong Kong, Tricor Standard Limited at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong not less than 48 hours before the time appointed for holding the meeting or any adjourned meeting (as the case may be).
3. The register of members of the Company will be closed from Thursday, 20 June 2024 to Thursday, 27 June 2024 (both days inclusive) for the purpose of determining entitlement of the shareholders of the Company to attend and vote at the aforesaid meeting, during which period no transfer of the Shares will be effected. In order to qualify for attending and voting at the aforesaid meeting, all transfers of the Shares accompanied by the relevant share certificates must be lodged with the Hong Kong share registrar of the Company, Tricor Standard Limited at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong for registration no later than 4:30 p.m. on Wednesday, 19 June 2024.
4. In order to determine the entitlement of the shareholders to receive the proposed final dividend, if approved, the register of members of the Company will be closed from Monday, 5 August 2024 to Tuesday, 6 August 2024, no transfer of the Shares will be registered on that day. In order to be eligible to receive the proposed final dividend, all transfers of the Shares accompanied by the relevant share certificates and appropriate transfer forms must be lodged with the Company's share registrar in Hong Kong, Tricor Standard Limited at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong for registration not later than 4:30 p.m. on Friday, 2 August 2024.